CC-99712 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).
| SparkCures ID | 358 |
|---|---|
| Developed By | Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb |
| Generic Name | CC-99712 |
| Treatment Classifications | |
| Treatment Targets |
There are no resources, links or videos to display for this treatment.